Significance Statement {#s1}
======================

Progesterone binds to the progestin receptor (PR) isoforms, PR-A and PR-B, in the brain to profoundly influence female reproduction, brain development, neuroprotection, and stress. We combined mass spectrometry and reverse phase protein arrays to identify mouse hypothalamic proteins that function in synaptic plasticity, transcription, translation, and energy metabolism and interacted with PR in a ligand-dependent and isoform-specific manner. In addition, progesterone increased synaptic density in primary cortical neurons, suggesting a function for progesterone in synapse formation in cortical neurons. Taken together, these findings provide evidence for novel functions of PR in synaptic modulation and energy homeostasis to affect health and disease.

Introduction {#s2}
============

Progestins, a class of steroid hormones, act in the brain to profoundly influence development ([@B6]; [@B118]); neuroprotection ([@B109]; [@B104]; [@B47]; [@B110]); reproductive behavior ([@B103]; [@B7]); learning, memory, and cognition ([@B46]; [@B95]; [@B118]); and anxiety and stress ([@B76]; [@B9]; [@B56]; [@B117]). In addition, progestins have been implicated in a variety of human diseases, including neurodegeneration and breast cancer ([@B90]; [@B15]; [@B81]; [@B31]).

Progestins elicit many of their effects by binding to progestin receptors (PR), which exist as two isoforms in mammals, an N-terminally truncated PR-A and a full-length PR-B ([@B116]). Both isoforms share a C-terminal ligand binding domain, a DNA binding domain, and two transactivation domains ([@B43]; [@B53]). Interestingly, a third transactivation domain exclusive to PR-B, and a PR-A specific inhibitory region, have been identified, allowing differential functions by the isoforms ([@B44]). Isoform-specific transcriptional activation by PR has been observed *in vitro* and *in vivo* ([@B96]; [@B35]; [@B25]; [@B20]; [@B90]; [@B77]). Isoform-specific knockout mice reveal that although PR-A in the mouse hypothalamus is the primary mediator of female sexual behavior, both isoforms are required for the full behavioral response ([@B69]). In support, PR-A and PR-B are differentially expressed in the female mouse hypothalamus ([@B1]).

PR associate with multiple proteins, including nuclear receptor coactivators, which stabilize the receptor complex and enhance transcription ([@B42]; [@B38]; [@B102]). In the female mouse hypothalamus, the PR isoforms are differentially expressed with steroid receptor coactivator-1 (SRC-1, also named NCOA1) and SRC-2 (NCOA2; [@B1]). In addition, SRC-1 and SRC-2 from hypothalamus associate with the PR isoforms in a ligand-dependent and isoform-specific manner ([@B74]; [@B126]) and modulate hormone-dependent gene expression and female sexual behavior ([@B2]; [@B75]; [@B73]). Taken together, these studies indicate that nuclear receptor coactivators are important in PR function in the brain.

PR act through both classic and nonclassic pathways in the brain and other progestin-responsive tissues. For example, in the hypothalamus, PR activation induces lordosis in female rodents through transcriptional regulation ([@B62]; [@B73]) as well as nonclassic kinase activation ([@B37]; [@B69]). PRs are present in synapses ([@B120]; [@B72]) and rapidly alter dendritic spine densities in rat hippocampus ([@B122]; [@B70]), cortical neurons ([@B19]; [@B94]), and hypothalamus ([@B39]).

Although we are gaining a better understanding of distinct functions of the PR isoforms in brain, little is known about the mechanisms involved. Therefore, to investigate the factors that could contribute to the differential function of the PR isoforms in brain, we have combined mass spectrometry (MS) and reverse phase protein array (RPPA) in a functional proteomic analysis to identify proteins from adult female mouse hypothalamus that interact with mouse PR-A and PR-B. In addition, given the identification of many synaptic proteins that interact with PR in the present study, we tested the hypothesis that progestins influence synaptic plasticity by increasing synapse formation in cortical neurons.

Materials and Methods {#s3}
=====================

Animals {#s3A}
-------

Female C57/BL6 mice were bred in the Wellesley College Animal Facility (Wellesley, MA). Mice were group-housed (three to six/group) under a 12-h light/dark cycle. Food and water were available *ad libitum*. All animal procedures were approved by the Institutional Animal Care and Use Committee of Wellesley College and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Tissue collection and preparation {#s3B}
---------------------------------

Mice (8 to 10 wks old) were bilaterally ovariectomized under 1.5% isoflurane. One week later, mice were killed by asphyxiation under CO~2~. Brains were quickly removed, and hypothalamic tissue was dissected using coordinates from the mouse brain atlas ([@B82]), immediately frozen on dry ice, and stored at --80°C until homogenization. Hypothalami from four to eight mice were pooled to generate each sample and lysed in lysis buffer containing 10 m[m]{.smallcaps} Tris, 10% glycerol, 400 m[m]{.smallcaps} NaCl, 1 m[m]{.smallcaps} dithiothreitol (DTT), and 1 m[m]{.smallcaps} EDTA (pH 7.4) with protease inhibitors (1:10 dilution, P2714, Sigma-Aldrich). Lysates were incubated on ice for 30 min followed by centrifugation at 13,200 × *g* for 30 min at 4°C. Supernatants containing proteins were stored at --80°C.

Glutathione S-transferase--tagged mouse progestin receptors {#s3C}
-----------------------------------------------------------

Mouse PR-B cDNA was cloned into the CMV-based mammalian cell expression plasmid pcDNAI (Invitrogen) by insertion into the PspHI/EcoRI site. Mouse PR-A cDNA was prepared by partial digest of mouse PR-B cDNA, ligated into the pBlueBacHis2B transfer plasmid, and inserted into the BamHI/EcoRV site of pcDNAI. pAcG2T baculovirus expression vector (BD Biosciences) was used for expression of PR-A and PR-B as fusion proteins, containing an N-terminal glutathione S-transferase (GST) tag. Site-directed mutations were performed using QuikChange XL Site-directed Mutagenesis Kit (Stratagene). The mutated sites were used to ligate cDNAs of mouse PR-A and PR-B into the respective restriction sites of pAcG2T. Mouse PR-A containing BamHI and EcoRI sites was ligated into the respective sites of the mutated pAcG2T. Similarly, mouse PR-B containing EcoRI and NotI sites was ligated into the respective sites of the mutated pAcG2T. Both DNA constructs were fully sequenced from the start of the GST to the end of the mouse PR subtype (Genewiz).

After the full sequences were confirmed, recombinant proteins containing full-length mouse PR-A or PR-B fused to a GST tag were expressed in *Spodoptera frugiperda* (Sf9) insect cells by the Baculovirus/Monoclonal Antibody Facility of the Baylor College of Medicine as described previously ([@B114]; [@B74]; [@B126]). Insect cell cultures for GST-PR were incubated with saturating doses of 200 n[m]{.smallcaps} of the PR agonist R5020 or in the absence of PR ligand. Sf9 cell pellets were homogenized in buffer containing 10 m[m]{.smallcaps} Tris, 10% glycerol, 400 m[m]{.smallcaps} NaCl, 1 mM DTT, and 1 m[m]{.smallcaps} EDTA (pH 7.4) with protease inhibitors. Homogenates were incubated on ice for 30 min, and then centrifuged at 13,200 × *g* for 30 min at 4°C. Supernatants containing proteins were stored at --80°C.

GST-PR pull-down {#s3D}
----------------

GST-PR pull-down assays were performed as described previously ([@B74]; [@B126]). Briefly, glutathione Sepharose 4B packed resin (50 µL, 0.05 mg/mL, GE Healthcare) was added to siliconized centrifuge tubes and pretreated with ovalbumin (1 mg/mL, Thermo Fisher Scientific) for 15 min on an end-over-end rotator at 4°C. Resin was rinsed three times with TG buffer (20 m[m]{.smallcaps} Tris--HCl and 10% glycerol) containing 1 [m]{.smallcaps} urea and 100 m[m]{.smallcaps} NaCl (TG-NaCl-U, pH 8.0). GST-PRA or GST-PRB bound to the agonist R5020, or unliganded, were used for pull-downs. R5020 is a synthetic progestin that binds with a similar affinity to both PR-A and PR-B ([@B105]; [@B16]). Equal amounts of recombinant mouse GST-PR suspended in TG buffer with 1 [m]{.smallcaps} urea (TG-U, pH 8.0) were added to resin and incubated on a rotator at 4°C for 1 h. After incubation, resin with immobilized GST-PR was washed four times with TG-NaCl-U (with reducing urea concentrations of 1, 0.5, 0.25, and 0 [m]{.smallcaps}). Equal amounts of pooled hypothalamic homogenates were added to immobilized GST-PR and incubated on a rotator for 1 h at 4°C. The resins were washed four times with TG-NaCl (without urea).

Proteins bound to GST-PR resin were eluted in specific buffers for each of the analyses. For Western blots, samples were eluted by boiling for 5 min in 2× Laemmli sample buffer (Bio-Rad) with 35 m[m]{.smallcaps} DTT (Sigma-Aldrich) for 5 min. For MS analysis, GST-PR and proteins bound to resin were eluted by incubating in 250 m[m]{.smallcaps} glutathione elution buffer (in 50 m[m]{.smallcaps} Tris-HCl, pH 8.0) at 4°C for 10 min. Samples for RPPA analysis were boiled in SDS sample buffer (Invitrogen) with 2.5% β-mercaptoethanol for 5 min.

Mass spectrometry analysis {#s3E}
--------------------------

Pull-down assays for MS were performed with GST-PRA or GST-PRB, unliganded or bound to R5020. Tryptic peptides prepared as previously described ([@B74]) for each receptor type and ligand condition were block-randomized and analyzed in triplicate ([@B80]) by nano-LC-MS/MS using a nano-LC chromatography system (UltiMate 3000 RSLCnano, Dionex), coupled online to a Thermo Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific) through a nanospray ion source (Thermo Fisher Scientific). Chromatographic columns were made from 75-µm-ID polyimide-coated fused silica capillary (Polymicro Technologies) packed with 5 µm Zorbax SB-C18 reversed-phase packing (Agilent) to a length of 10 cm by using a Pressure Injection Cell (NextAdvance). The trap column was prepared in the same manner but to a length of 1 cm. After equilibrating the column in 98% solvent A (0.1% formic acid in water) and 2% solvent B (0.1% formic acid in acetonitrile), the samples (3 µL in solvent A) were injected onto the trap column and eluted (400 nL/min) by gradient elution onto the C18 column as follows: isocratic at 2% B, 0--5 min; 2% to 32% B, 5--49 min; 32% to 90% B, 49--50 min; isocratic at 90% B, 50--54.5 min; 90% to 2% B, 54.5--55 min; and isocratic at 2% B, 55--60 min. All LC-MS/MS data were acquired using XCalibur, version 2.1.0 (Thermo Fisher Scientific) in positive ion mode using a top speed data-dependent acquisition method with a 2-s cycle time. The survey scans (*m*/*z* 350--1600) were acquired in the Orbitrap at 120,000 resolution (at *m*/*z* 400) in profile mode, with a maximum injection time of 50 ms and an automatic gain control (AGC) target of 400,000 ions. The S-lens RF level was set to 60. Isolation was performed in the quadrupole with a 1.6-Da isolation window, and CID MS/MS acquisition was performed in profile mode in the ion trap using rapid scan rate, with the following settings: parent threshold, 10,000; isolation width, 1.6 Da; normalized collision energy, 35%; maximum injection time, 150 ms; and AGC target, 10,000 ions. Monoisotopic precursor selection and charge state filtering were on, with charge states 2--4 included. Dynamic exclusion was used to remove selected precursor ions for 60 s after acquisition of one MS/MS spectrum.

Proteomic data analysis of MS samples {#s3F}
-------------------------------------

All data files were searched against a Uniprot mouse database (June 2014 version, 16,728 proteins), appended with the Common Repository of Adventitious Proteins contaminant database using PEAKS ([@B65]; [@B41]; [@B127]). Searches were performed with a parent ion tolerance of 10 ppm, fragment ion tolerance of 0.80 Da, fixed modification of carbamidomethyl (C), and variable modifications of oxidation (M) and phosphorylation (STY). Trypsin was specified as the enzyme, allowing for two missed cleavages and one nonspecific cleavage. False discovery rate (FDR) estimation was allowed. The resulting peptide-spectrum matches \>1% FDR were used to generate a spectral library for subsequent quantitative analysis. Data files for each pair of samples were imported into Skyline ([@B66]) for label-free quantitative analysis ([@B98]). After manual verification of all peaks, triplicate peptide intensities were used to calculate fold changes and *p*-values.

Reverse phase protein array analysis {#s3G}
------------------------------------

Hypothalamic tissue from adult female mice (*n* = 32) was pooled into four different groups. Similar to MS, RPPA assays were performed using pull-downs with GST-PRA and GST-PRB bound to R5020 or unliganded. RPPA assays were conducted as described previously ([@B18]) with the following modifications. Proteins associating with GST-PR bound to resins were eluted in 2× Tris-glycine SDS buffer with 2.5% β-mercaptoethanol and mixed with modified Tissue Protein Extraction Reagent ([@B85]) and a cocktail of protease and phosphatase inhibitors (Roche Life Science; [@B18]). A 2470 Arrayer (Aushon BioSystems) with a 40-pin (185 µm) configuration was used to spot samples and control lysates onto nitrocellulose-coated slides (Grace Bio-labs) using an array format of 960 lysates/slide (2880 spots/slide). The slides were processed as described previously ([@B18]) and probed with a set of 212 antibodies ([Table 1](#T1){ref-type="table"}) against 140 total proteins and 72 proteins phosphorylated on specific sites using an automated slide stainer, Autolink 48 (Dako). Each slide was incubated with one specific primary antibody. Negative control slides were incubated with antibody diluent instead of primary antibody. Primary antibody binding was detected using a biotinylated secondary antibody followed by streptavidin-conjugated IRDye680 fluorophore (LI-COR Biosciences). The total protein content of each spotted lysate was assessed by fluorescent staining with Sypro Ruby Protein Blot Stain according to the manufacturer's instructions (Invitrogen).

###### 

List of antibodies used for RPPA analysis

  **Antibody name**                               Company                    Catalog \#         Host
  ----------------------------------------------- -------------------------- ------------------ --------
  14-3-3zeta,gamma,eta_R\_V                       EMD Millipore (Upstate)    06-408             Rabbit
  Akt_R\_V                                        CST                        9272               Rabbit
  *p*-Akt(S473)\_R_V                              CST                        9271               Rabbit
  *p*-Akt(T308)\_R_V                              CST                        9275               Rabbit
  *p*-ALK(3B4)(Y1586)\_R_V                        CST                        3348               Rabbit
  *p*-ALK(Y1604)\_R_V                             CST                        3341               Rabbit
  *p*-AMPKa(40H9)(T172)\_R_V                      CST                        2535               Rabbit
  *p*-AMPKa1(S485)\_R_V                           CST                        4184               Rabbit
  *p*-AMPKb1(S108)\_R_V                           CST                        4181               Rabbit
  Annexin1_R\_V                                   Invitrogen                 71-3400            Rabbit
  ATM_R\_V                                        Abcam                      ab32420            Rabbit
  ATR_R\_V                                        CST                        2790               Rabbit
  *p*-ATR(S428)\_R_V                              CST                        2853               Rabbit
  *p*-AuroraA(T288)/B(T232)/C(T198)\_R_V          CST                        2914               Rabbit
  AuroraA/AIK_R\_V                                CST                        3092               Rabbit
  *p*-Axl(D12B2)(Y702)\_R_V                       CST                        5724               Rabbit
  Bad_R\_V                                        CST                        9292               Rabbit
  *p*-Bad(S112)\_R_V                              CST                        9291               Rabbit
  *p*-Bad(S136)\_R_V                              CST                        9295               Rabbit
  *p*-Bad(S155)\_R_V                              CST                        9297               Rabbit
  Bak_R\_V                                        CST                        3814               Rabbit
  Bax_R\_V                                        CST                        2772               Rabbit
  *p*-Bcl2(5H2)(S70)\_R_V                         CST                        2827               Rabbit
  *p*-Bcl2(T56)\_R_V                              CST                        2875               Rabbit
  BRCA1_R\_V                                      EMD Millipore (Upstate)    07-434             Rabbit
  BRCA2_R\_V                                      CST                        9012               Rabbit
  Caspase-3_R\_V                                  CST                        9662               Rabbit
  *p*-Beta-Catenin(S33/37/T41)\_R_V               CST                        9561               Rabbit
  Caveolin-1(D46G3)XP_R\_V                        CST                        3267               Rabbit
  *p*-Caveolin-1(EPR2288Y)(Y14)\_R_V              Abcam-Epitomics            2267-1             Rabbit
  CD24(FL-80)\_R_V                                Santa Cruz Biotechnology   sc-11406           Rabbit
  *p*-Chk1(S345)\_R_V                             CST                        2341               Rabbit
  *p*-Chk2(S33/35)\_R_V                           CST                        2665               Rabbit
  Claudin-1_R\_V                                  CST                        4933               Rabbit
  c-Met_R\_V                                      Abcam                      ab51067            Rabbit
  *p*-c-Myc(T58)\_R_V                             Abcam                      ab28842            Rabbit
  DKK1_R\_V                                       CST                        4687               Rabbit
  EGFR(D38B1)XP_R\_V                              CST                        4267               Rabbit
  EGFR(L858R)\_R_V                                CST                        3197               Rabbit
  *p*-EGFR(S1046/1047)\_R_V                       CST                        2238               Rabbit
  *p*-EGFR(Y1045)\_R_V                            CST                        2237               Rabbit
  *p*-EGFR(Y1148)\_R_V                            CST                        4404               Rabbit
  *p*-EGFR(Y1173)\_R_V                            Invitrogen (BioSource)     44-794G            Rabbit
  *p*-EGFR(Y1173)(53A5)\_R_V                      CST                        4407               Rabbit
  *p*-EGFR(Y1068)(D7A5)XP_R\_V                    CST                        3777               Rabbit
  Ezh2(D2C9)XP_R\_V                               CST                        5246               Rabbit
  FGFR1(D8E4)XP_R\_V                              CST                        9740               Rabbit
  FoxO1(C29H4)\_R_V                               CST                        2880               Rabbit
  FSP1/S100A4_R\_V                                EMD Millipore              Jul-74             Rabbit
  *p*-HER2/ErbB2(Y1248)\_R_V                      CST                        2247               Rabbit
  *p*-HER2/ErbB2(Y877)\_R_V                       Imgenex                    IMG-90185          Rabbit
  HER3/ErbB3_R\_V                                 CST                        4754               Rabbit
  *p*-HER3/ErbB3(Y1197)\_R_V                      CST                        4561               Rabbit
  HDAC1_R\_V                                      CST                        2062               Rabbit
  HDAC3_R\_V                                      CST                        2632               Rabbit
  HDAC4_R\_V                                      CST                        2072               Rabbit
  HDAC6_R\_V                                      Santa Cruz Biotechnology   sc-11420           Rabbit
  ILK1_R\_V                                       CST                        3862               Rabbit
  *p*-Jak1(Y1022/1023)\_R_V                       CST                        3331               Rabbit
  Kit-c_R\_V                                      Abcam                      ab32363            Rabbit
  Lipocalin-1_R\_V                                Santa Cruz Biotechnology   sc-66943           Rabbit
  LRP6_R\_V                                       CST                        2560               Rabbit
  MEK1_R\_V                                       Abcam-Epitomics            1235-1             Rabbit
  *p*-MEK1/2(S217/221)\_R_V                       CST                        9121               Rabbit
  *p*-Met(Y1234/1235)\_R_V                        CST                        3077               Rabbit
  MMP-9_R\_V                                      CST                        3852               Rabbit
  mTOR_R\_V                                       CST                        2972               Rabbit
  *p*-mTOR(D9C2)XP(S2448)\_R_V                    CST                        5536               Rabbit
  Notch1(C44H11)\_R_V                             CST                        3268               Rabbit
  *p*-p27(T187)\_R_V                              Invitrogen (Zymed)         71-7700            Rabbit
  *p*-p27/KIP1(T198)\_R_V                         Abcam                      ab64949            Rabbit
  p27/KIP1(C-term)\_R_V                           Abcam-Epitomics            ab32034(1591-1)    Rabbit
  p38/MAPK_R\_V                                   CST                        9212               Rabbit
  *p*-p38(D3F9) XP(T180/Y182)\_R_V                CST                        4511               Rabbit
  p44/42MAPK(Erk1/2)\_R_V                         CST                        9102               Rabbit
  *p*-p44/42MAPK(Erk1/2)(T202/Y204)(197G2)\_R_V   CST                        4377               Rabbit
  p53_R\_V                                        CST                        9282               Rabbit
  *p*-p53(S15)\_R_V                               CST                        9284               Rabbit
  p70S6K_R\_V                                     CST                        9202               Rabbit
  *p*-p70S6K(S371)\_R_V                           CST                        9208               Rabbit
  *p*-p70S6K(T389)\_R_V                           CST                        9205               Rabbit
  *p*-p70S6K(T412)\_R_V                           EMD Millipore (Upstate)    07-018             Rabbit
  *p*-PDGFRa(23B2)(Y754)\_R_V                     CST                        2992               Rabbit
  PDGFRb(28E1)\_R_V                               CST                        3169               Rabbit
  *p*-PDK1(S241)\_R_V                             CST                        3061               Rabbit
  PIAS1_R\_V                                      CST                        3550               Rabbit
  PTEN(D4.3)XP_R\_V                               CST                        9188               Rabbit
  *p*-PTEN(S380)\_R_V                             CST                        9551               Rabbit
  *p*-RafB(S445)\_R_V                             CST                        2696               Rabbit
  RANKL_R\_V                                      Novus                      NBP1-31140         Rabbit
  *p*-Ret(Y905)\_R_V                              CST                        3221               Rabbit
  Slug(C19G7)\_R_V                                CST                        9585               Rabbit
  *p*-Smad2(S465/467)\_R_V                        CST                        3101               Rabbit
  SOCS1(A156)\_R_V                                CST                        3950               Rabbit
  SOCS3_R\_V                                      CST                        2923               Rabbit
  Sox2(D6D9) XP_R\_V                              CST                        3579               Rabbit
  *p*-Src(Y527)\_R_V                              CST                        2105               Rabbit
  Stat1_R\_V                                      CST                        9172               Rabbit
  *p*-Stat1(Y701)\_R_V                            CST                        9171               Rabbit
  *p*-Stat2(Y690)\_R_V                            CST                        4441               Rabbit
  *p*-Stat3(S727)\_R_V                            CST                        9134               Rabbit
  *p*-Stat4(Y693)\_R_V                            CST                        5267               Rabbit
  *p*-Stat5(Y694)\_R_V                            CST                        9351               Rabbit
  Stat6_R\_V                                      CST                        9362               Rabbit
  *p*-Stat6(Y641)\_R_V                            CST                        9361               Rabbit
  *p*-Tuberin/TSC2(T1462)\_R_V                    CST                        3611               Rabbit
  Vimentin(D21H3)XP_R\_V                          CST                        5741               Rabbit
  Wnt5a/b(C27E8)\_R_V                             CST                        2530               Rabbit
  YAP(H125)\_R_V                                  Santa Cruz Biotechnology   sc-15407           Rabbit
  ZO-1_R\_V                                       CST                        5406               Rabbit
  Caspase-7_R\_V                                  CST                        9491               Rabbit
  VEGFR2(55B11)\_R_V                              CST                        2479               Rabbit
  Stat5a(L-20)\_R_V                               Santa Cruz Biotechnology   sc-1081            Rabbit
  SOX9_R\_V                                       EMD Millipore (Upstate)    AB5535             Rabbit
  *p*-SAPK/JNK(T183/Y185)\_R_V                    CST                        4668               Rabbit
  Zeb1_R\_V                                       Novus                      NBP1-05987         Rabbit
  PHF8(pAb)\_R_V                                  Active Motif               39711              Rabbit
  ASH2_R\_V                                       Bethyl Laboratories        A300-489A          Rabbit
  CBP(A-22)\_R_V                                  Santa Cruz Biotechnology   sc-369             Rabbit
  c-Fos(9F6) \_R_V                                CST                        2250               Rabbit
  CHAF1A(D77D5)XP_R\_V                            CST                        5480               Rabbit
  c-Jun(60A8)\_R_V                                CST                        9165               Rabbit
  CRSP1-TRAP220_R\_V                              Bethyl Laboratories        A300-793A          Rabbit
  CtBP2_R\_V                                      CST                        13256              Rabbit
  Cyclin C_R\_V                                   Santa Cruz Biotechnology   sc-1061            Rabbit
  DRIP130_R\_V                                    Abcam                      ab70450            Rabbit
  FBX011_R\_V                                     Abcam                      ab72200            Rabbit
  FoxK2_R\_V                                      CST                        12008              Rabbit
  KLF4_R\_V                                       CST                        12173              Rabbit
  MED12-Abcam_R\_V                                Abcam                      ab70842            Rabbit
  p300(C-20)\_R_V                                 Santa Cruz Biotechnology   sc-585             Rabbit
  *p*-c-Fos(S32)\_R_V                             CST                        5348               Rabbit
  PPP1R10(EPR11706)\_R_V                          Abcam                      ab173285           Rabbit
  Stat3(D3Z2G)\_R_V                               CST                        12640              Rabbit
  *p*-TRAP220-MED1(T1457)\_R_V                    Abcam                      ab60950            Rabbit
  HIF-2A(D9E3)\_R_V                               CST                        7096               Rabbit
  *p*-c-Jun(S63)\_R_V                             CST                        9261               Rabbit
  Sin3b_R\_V                                      Abcam                      ab101841           Rabbit
  *p*-Rb(S807/811)\_R_V                           CST                        9308               Rabbit
  *p*-Rb(S780)(C84F6)\_R_V                        CST                        3590               Rabbit
  *p*-FAK(Y576/577)\_R_V                          CST                        3281               Rabbit
  Ki67_R\_V                                       Vector Laboratories        VP-K451            Rabbit
  Integrina4(D2E1)XP_R\_V                         CST                        8440               Rabbit
  Integrina5_R\_V                                 CST                        4705               Rabbit
  IntegrinaV_R\_V                                 CST                        4711               Rabbit
  Integrinb1(D2E5)\_R_V                           CST                        9699               Rabbit
  Integrinb3(D7X3P)XP_R\_V                        CST                        13166              Rabbit
  Integrinb4_R\_V                                 CST                        4707               Rabbit
  PI3Kp85_R\_V                                    CST                        4292               Rabbit
  AMPKa(23A3)\_R_V                                CST                        2603               Rabbit
  PI3Kp110a(C73F8)\_R_V                           CST                        4249               Rabbit
  ERa(SP1)\_R_V                                   Thermo Fisher Scientific   RM-9101-S1         Rabbit
  MEK6_R\_V                                       Abcam                      ab52937            Rabbit
  p21_R\_V                                        CST                        2947               Rabbit
  Atg12(D88H11)\_R_V                              CST                        4180               Rabbit
  Beclin-1(D40C5)\_R_V                            CST                        3495               Rabbit
  Caspase-3(Asp175)\_R_V                          CST                        9661               Rabbit
  Beta-Catenin(CT)\_R_V                           Invitrogen                 71-2700            Rabbit
  Atg3_R\_V                                       CST                        3415               Rabbit
  Atg7_R\_V                                       CST                        8558               Rabbit
  LC3A(D50G8)XP_R\_V                              CST                        4599               Rabbit
  LC3B(D11)XP_R\_V                                CST                        3868               Rabbit
  *p*-EGFR(Y845)\_R_V                             CST                        2231               Rabbit
  *p*-EGFR(Y992)\_R_V                             CST                        2235               Rabbit
  ErbB2/HER2(Y1248)\_R_V                          Imgenex                    IMG-90189          Rabbit
  *p*-SHC(2431)(Y317)\_R_V                        CST                        2431               Rabbit
  SRD5A1_R\_V                                     Novusbio                   H00006715-D01P     Rabbit
  FAS_R\_V                                        CST                        3189               Rabbit
  HexokinaseII(C64G5)\_R_V                        CST                        2867               Rabbit
  PFKFB3 (C-terminal)\_R_V                        Abcam                      ab135820           Rabbit
  RRM2 (EPR11820)\_R_V                            Abcam                      ab172476           Rabbit
  *p*-Stat1(Y701)(D4A7)\_R_V                      CST                        7649               Rabbit
  GLDC_R\_V                                       CST                        12794              Rabbit
  GLS1_R\_V                                       Proteintech                20170-1-AP         Rabbit
  LDHA_R\_V                                       CST                        2012               Rabbit
  PHGDH_R\_V                                      CST                        13428              Rabbit
  PKM2_R\_V                                       Bethyl Laboratories        A303-660A-M        Rabbit
  PKM1/2_R\_V                                     CST                        3190               Rabbit
  Bcl-xL_R\_V                                     CST                        2762               Rabbit
  E-Cadherin(24E10)\_R_V                          CST                        3195               Rabbit
  ALK(D5F3)XP_R\_V                                CST                        3633               Rabbit
  HER2/c-ErbB2_R\_V                               Dako                       A0485              Rabbit
  ALDH_M\_V                                       BD Biosciences             611194             Mouse
  *p*-ATM(S1981)\_M_V                             CST                        4526               Mouse
  Axl_M\_V                                        Abcam                      ab54803            Mouse
  CD24 Ab2(SN3b)\_M_V                             Thermo Fisher Scientific   MS-1279-P0         Mouse
  Chk2(1C12)\_M_V                                 CST                        3440               Mouse
  Cox-2_M\_V                                      BD Biosciences             610203             Mouse
  GATA3_M\_V                                      BD Biosciences             558686             Mouse
  GSK-3a/b_M\_V                                   Santa Cruz Biotechnology   SC-7291            Mouse
  HER2/c-ErbB2-P185_M\_V                          Invitrogen (BioSource)     AHO1011            Mouse
  HIF-1a_M\_V                                     BD Biosciences             610958             Mouse
  *p*-IkappaB-a(S32/36)\_M_V                      BD Biosciences             551818             Mouse
  S100A7/CBP_M\_V                                 Abnova                     H00006278-A01      Mouse
  Twist(Twist2C1a)\_M_V                           Santa Cruz Biotechnology   sc-81417           Mouse
  SRC-3(clone 1208/D1)\_M_V                       BCM-Mab                    in house           Mouse
  c-Myc(clone 1123)\_M_V                          BCM-Mab                    in house           Mouse
  SRC-2(TIF2)\_M_V                                BD                         610985             Mouse
  SRC-1(clone 1135/H4,1136/H4H6)\_M_V             BCM-Mab                    in house           Mouse
  PR(1294)\_M_V                                   Celetta                    in house_Celetta   Mouse
  Rb(4H1)\_M_V                                    CST                        9309               Mouse
  *p*-FAK(Y397)\_M_V                              BD Biosciences             611806             Mouse
  AR-441_M\_V                                     BCM                        NW-Mab70           Mouse
  AMPKa(F6)\_M_V                                  CST                        2793               Mouse
  Bcl2(Clone-124)\_M_V                            Dako                       M088729-2          Mouse
  c-Src(B-12)\_M_V                                Santa Cruz Biotechnology   sc-8056            Mouse
  IGF-IR(3B7)\_M_V                                Santa Cruz Biotechnology   sc-462             Mouse
  Laminin5_M\_V                                   EMD Millipore              MAB19562           Mouse
  Aromatase-A(Clone 677H7F10)\_M_V                BCM-Mab                    in house           Mouse
  AOX1(cloneAO15)\_M_V                            Sigma-Aldrich              SAB4200562         Mouse
  IDH2_M\_V                                       Abcam                      ab55271            Mouse
  SCD1 (CD.E10)\_M_V                              Abcam                      ab19862            Mouse

Host species for the antibodies and validation status are reported. R, rabbit; M, mouse and V, validated.

Fluorescence-labeled slides were scanned on a GenePix 4400 AL scanner. Each slide, along with its accompanying negative control slide, was scanned at an appropriate photomultiplier tube to obtain optimal signal for this specific set of samples. The images were analyzed with GenePix Pro 7.0 (Molecular Devices). Total fluorescence signal intensities for each spot were obtained after subtraction of the local background signal for each slide and were then normalized for variation in total protein, background, and nonspecific labeling using a group-based normalization method as described ([@B18]). Each image, along with its normalized data, was evaluated for quality through manual inspection and comparison with control samples. Specific fluorescence intensity signals of 50 units or less was taken as assay cutoff for a positive reaction, resulting in 195 remaining proteins, of the 212 ([Table 1](#T1){ref-type="table"}), to be analyzed.

Analysis of data from RPPA assays {#s3H}
---------------------------------

After data were normalized to PR signal in the assay or to target protein input, it was determined that normalizing to PR produced the most consistent results. The effects of receptor type and hormone treatment were analyzed via two-way ANOVA using R. We identified proteins with FDR-adjusted *p*-values \<0.05. For this subset of identified proteins, relative fold changes between the liganded and unliganded receptor were calculated for each isoform. For proteins displaying a positive interaction with the liganded PR, a two-fold change was used as a cutoff. For proteins showing a positive association with the unliganded PR, further stringency was maintained by setting a higher threshold of three-fold change, as with the MS data.

Western blot analysis {#s3I}
---------------------

Western blot analyses were performed on representative proteins: synapsin-I and synapsin-II (MS-identified) and SRC-1, SRC-2, FoxO1, MED12, c-Fos, and c-Jun (RPPA-identified) to validate findings from the MS and RPPA analyses. Western blots were conducted as described previously ([@B11]) with the modifications indicated below. For independent validation of the ligand-dependent interaction of PR with hypothalamic SRC-1 and SRC-2 determined by RPPA, protein homogenates from female mouse hypothalamus (*n* = 6, 5 mice per group) were prepared as described above. Pull-down samples were probed for SRC-1 and SRC-2 using a rabbit polyclonal antibody to 350--690 amino acids (aa) of human SRC-1 (1:250, \#sc-8995, Santa Cruz, RRID:[AB_2235896](https://scicrunch.org/resolver/AB_2235896)) and a rabbit polyclonal antibody to human SRC-2 (1:750, \#PA1-86392, Fisher Scientific, RRID:[AB_2103955](https://scicrunch.org/resolver/AB_2103955)), respectively. MED12, c-Fos and c-Jun were probed with rabbit polyclonal antibodies MED12 (1:200, \#ab70842, Abcam), c-Fos (1:200, \#5348, Cell Signaling Technology), and c-Jun (1:200, \#9261, Cell Signaling Technology), respectively. Fluorescently labeled donkey anti-goat AF488 and donkey anti-rabbit AF647 were used for detection of SRC-1 and SRC-2 (1:10,000, Invitrogen), respectively. Immunoreactive bands were detected and relative optical densities were quantified using a GelDoc Imager and Image Lab Software (Bio-Rad). Two-way ANOVA followed by Tukey's honestly significant difference was used (SPSS v.21) to examine the effect of ligand and receptor type. We identified differences with Tukey-adjusted *p*-values \<0.05. In addition, validation of MS findings of synapsin-I and synapsin-II by Western blot was conducted using a rabbit polyclonal antibody to synapsin-I (1:500, \#ab1543, Millipore, RRID:[AB_2200400](https://scicrunch.org/resolver/AB_2200400)) and a mouse monoclonal antibody to synapsin-II (0.3μg/mL, \#mabn1573, Millipore). Secondary antibodies donkey anti-rabbit AF647 and donkey anti-mouse AF488 (1:10,000, Invitrogen) were used for synapsin-I and synapsin-II, respectively.

In confirmation of findings by RPPA, interaction of PR with FoxO1 was analyzed by Western blot using a rabbit polyclonal FoxO1 antibody (1:250, \#2880, CST, RRID:[AB_2106495](https://scicrunch.org/resolver/AB_2106495)), the same as used for RPPA, followed by a donkey anti-rabbit AF647 secondary antibody (1:10,000, Invitrogen). For the detection of mouse GST-PR, a mouse monoclonal antibody directed against the N-terminal 165--534 aa of human PR-A and PR-B (PR 1294, 0.5 µg/mL), followed by a donkey anti-mouse AF488 secondary antibody (1:10,000, Invitrogen), was used.

Neuronal cultures {#s3J}
-----------------

Primary cortical neuronal cultures (mixed sex) were prepared from Sprague-Dawley rat E18 embryos as described previously ([@B106]). These cortical cultures display mature neuronal morphology (extensive arborizations and dendritic spines) and electrophysiological and cellular responses to synaptic activity, consistent with those seen in *in vivo*/*ex vivo* studies of mature neurons ([@B123]; [@B108]). Because our MS and RPPA data were collected from mature brain, cortical neurons, which recapitulate mature neuronal characteristics ([@B123]; [@B108]), were used in these studies.

Animals were habituated for 3 d before experimental procedures, compliant with the Home Office Animals (Scientific Procedures) Act, UK, 1986. Dissociated cells were plated onto 18-mm glass coverslips (no. 1.5; 0117580, Marienfeld-Superior), coated with poly-[d]{.smallcaps}-lysine (0.2 mg/ml, Sigma-Aldrich), at a density of 3 × 10^5^/well equal to 857/mm^2^ and cultured in feeding medium: neurobasal medium (21103049) supplemented with 2% B27 (17504044), 0.5 m[m]{.smallcaps} glutamine (25030024), and 1% penicillin:streptomycin (15070063; all reagents from Invitrogen). Neuron cultures were maintained in the presence of 200 μ[m d]{.smallcaps},[l]{.smallcaps}-amino-phosphonovalerate ([d]{.smallcaps},[l]{.smallcaps}-APV, ab120004, Abcam) beginning on 4 d *in vitro* (DIV 4) to maintain neuronal health for long-term culturing and reduce cell death due to excessive Ca^2+^ cytotoxicity via overactive NMDA receptors ([@B106]). Half-medium changes were performed twice weekly until the desired age (DIV 23--25).

Pharmacological treatment of neuronal cultures {#s3K}
----------------------------------------------

All pharmacological treatments were performed on DIV 25--30 primary cortical neuronal cultures. Treatments were conducted in feeding medium: neurobasal medium (21103049) supplemented with 2% B27, 0.5 m[m]{.smallcaps} glutamine, and 1% penicillin:streptomycin in the presence of 200 μ[m d]{.smallcaps},[l]{.smallcaps}-APV. Progesterone (P4; Sigma-Aldrich, P6149) was dissolved in ethanol to a concentration of 31.8 m[m]{.smallcaps}, and 17β-estradiol (E2) was dissolved in dimethylsulfoxide to a final concentration of 1 m[m]{.smallcaps}. Both compounds were serially diluted to a 10× working concentration in feeding medium and applied directly to neuronal cultures. Final concentrations of P4 and E2 were 1 n[m]{.smallcaps}. Final concentration of solvent was \<0.01%: vehicle control was made up of solvent lacking compound, diluted as test compounds. Neuronal cultures were treated for 24 h, washed in PBS, and fixed in 4% formaldehyde/4% sucrose PBS for 10 min at room temperature followed by incubation in methanol prechilled to --20°C for 10 min at 4°C. Fixed neuronal cultures were then permeabilized and blocked simultaneously (2% normal goat serum, 5425S, Sigma-Aldrich, and 0.2% Triton X-100) before incubation with the following primary antibodies overnight: PSD95 mouse monoclonal antibody (1:1000; clone K28/43; \#73-028, NeuroMab, RRID:[AB_10698024](https://scicrunch.org/resolver/AB_10698024)), synapsin-I rabbit polyclonal antibody (1:200; \#5297, Cell Signaling Technologies), and MAP2 chicken polyclonal antibody (1:2000; \#AB104896, Abcam). Cultures were subsequently incubated with Alexa Fluor anti-rabbit 488, anti-mouse 568, and anti-chicken 633 secondary antibodies (1:750; Invitrogen) the following day for 1 h at room temperature ([@B106]).

Quantitative and statistical analysis of immunofluorescence {#s3L}
-----------------------------------------------------------

Confocal images of neurons were acquired with a Nikon A1-R confocal microscope using a 60× oil-immersion objective (NA 1.4; Nikon) as a *z*-series, *z*-step set to 0.5 µm. Two-dimensional maximum-projection reconstructions of images were generated, and morphometric analysis (puncta number and intensity) was conducted using MetaMorph software (Universal Imaging Corporation; [@B106]). Analyses of puncta were performed on spines from at least two dendrites (secondary or tertiary branches), totaling 100 µm, from each neuron. The linear density of each synaptic protein cluster was measured automatically using MetaMorph ([@B106]). Synaptic puncta were defined as synapsin-I puncta that contained PSD95 immunofluorescence greater than background; background fluorescence was the average background intensity from five regions of interest plus two standard deviations ([@B36]). Cultures that were directly compared were stained simultaneously and imaged with the same acquisition parameters. For each condition, 10--16 neurons from at least 3 separate experiments were used. Experiments were conducted blind to condition and on sister cultures.

All statistical analyses were performed in GraphPad. Differences in quantitative immunofluorescence were identified by a one-way ANOVA with Tukey correction for multiple comparisons. Error bars represent the standard error of the mean.

Results {#s4}
=======

Mass spectrometry {#s4A}
-----------------

To detect proteins from female mouse hypothalamus that associated with mouse PR in the presence or absence of hormone, MS analysis was performed on pull-down samples using GST-tagged PR. This unbiased approach identified many hypothalamic proteins that interact with one or both PR isoforms in a ligand-dependent manner ([Tables 2](#T2){ref-type="table"} and [2-1](#T2){ref-type="table"}). MS-identified proteins were categorized into the following groups based on their functions: (a) synaptic structure and function, (b) signal transduction, (c) transcription, (d) translation, and (e) metabolism. The proteins associated with synaptic structure and function was the largest group, containing 61% (20 of 35) of the MS-identified proteins that interacted with ligand-bound PR. Subsets of these synaptic proteins associated with PR-A only (9 proteins), PR-B only (7), or both isoforms (4) in a ligand-dependent manner, strongly indicating a function for both PR isoforms in synaptic physiology. More than 18% (6 of 35) of the identified PR-interacting proteins are transcriptional regulators, with two-thirds associating with PR-B only and the remaining one-third associating with PR-A only. Proteins involved in signal transduction, including kinases, comprised 9% (3 of 35) of the MS-identified proteins that associated with PR in the presence of ligand. We also identified the translational regulators 40S ribosomal protein S9 and 26S protease regulatory subunit 6A that associated only with PR-B in the presence of R5020. On the other hand, proteins with a role in cellular metabolism identified by MS interacted with liganded PR-A only ([Table 2](#T2){ref-type="table"}). Finally, consistent with previous studies ([@B3]; [@B49]), a large number of additional proteins interacted with unliganded PR-A, PR-B, or both ([Table 2-1](#tab2-1){ref-type="supplementary-material"}).

###### 

Proteins from mouse hypothalamus, identified by MS analysis, associate with mouse PR in a ligand-dependent manner

  ---------------------------------------------------------- ---------------- ------------ ------------------------ ------------------------
  **Synaptic structure and function**                        UniProt symbol   Uniprot ID   PR-A (R5020/no ligand)   PR-B (R5020/no ligand)
  Synapsin-I                                                 SYN1             O88935       \+                       \+
  Synapsin-II                                                SYN2             Q64332       \+                       \+
  Synapsin-III                                               SYN3             Q8JZP2                                \+
  Synaptogyrin-III                                           SNG3             Q8R191       \+                       
  α-Synuclein                                                SYUA             O55042                                \+
  Septin-5                                                   SEPTM5           Q9Z2Q6                                \+
  Desmoglein-4                                               Desmoglein-4     Q7TMD7       \+                       
  Desmoplakin                                                DESP             E9Q557       \+                       
  Junction plakoglobin                                       PLAK             Q02257       \+                       
  Leucine-rich repeat-containing protein 15                  LGR4             A2ARI4       \+                       
  Hemoglobin subunit β-1                                     HBB1             P02088       \+                       
  β-Actin-like protein 2                                     ACTBL            Q8BFZ3                                \+
  Tubulin α-1A chain                                         TBA1A            P68369                                \+
  Tubulin α-1B chain                                         TBA1B            P05213                                \+
  Tubulin β-2A chain                                         TBB2A            Q7TMM9       \+                       \+
  Tubulin β-3 chain                                          TBB3             Q9ERD7       \+                       
  Tubulin β-4A chain                                         TBB4A            Q9D6F9       \+                       
  Tubulin β-4B chain                                         TBB4B            P68372       \+                       
  Tubulin β-5 chain                                          TBB5             P99024       \+                       \+
  Tubulin β-6 chain                                          TBB6             Q922F4                                \+
  **Signal transduction**                                                                                           
  Mitogen-activated protein kinase 1                         MK01             P63085                                \+
  14-3-3 protein ζ/δ                                         1433Z            P63101                                \+
  Rab GDP dissociation inhibitor β                           GDIB             Q61598                                \+
  **Transcription**                                                                                                 
  Elongation factor 1β                                       TIF1B            Q62318       \+                       
  Histone H4                                                 H4               P62806       \+                       
  Brain acid soluble protein 1                               A4               P12023                                \+
  Heterogeneous nuclear ribonucleoprotein D-like             HNRDL            Q9Z130                                \+
  Heterogeneous nuclear ribonucleoprotein U-like protein 1   HNRL1            Q8VDM6                                \+
  Probable ATP-dependent RNA helicase DDX5                   DDX5             Q61656                                \+
  **Translation**                                                                                                   
  26S protease regulatory subunit 6A                         PRS6A            O88685                                \+
  40S ribosomal protein S9                                   RS9              Q6ZWN5                                \+
  **Metabolism**                                                                                                    
  Creatine kinase B-type                                     KCRB             Q04447       \+                       
  Phytanoyl-CoA hydroxylase-interacting protein-like         PHIPL            Q8BGT8       \+                       
  ---------------------------------------------------------- ---------------- ------------ ------------------------ ------------------------

Proteins associate with PR with R5020/no ligand at a ratio ≥2 and *p* \< 0.05. [Table 2-1](#tab2-1){ref-type="supplementary-material"} shows proteins identified by MS that associate with PR in the absence of ligand.
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Proteins that interact with mouse PR-A, mouse PR-B, or both isoforms in the absence of ligand, as identified by MS, with a ratio of no ligand/R5020 ≥3 and *p* \< 0.05. Download Table 2-1, DOC file.

To validate findings by MS, pull-down samples were analyzed by Western blot for select synaptic proteins, the largest functional group identified in the MS analysis. Western blot results showed an increased interaction of synapsin-Ia and synapsin-Ib with both PR-A and PR-B in the presence of R5020 compared with no ligand ([Fig. 1](#F1){ref-type="fig"}). Similarly, the synapsin-II isoforms, synapsin-IIa and synapsin-IIb, interacted with PR-A and PR-B in a ligand-dependent manner, further extending the MS findings.

![Hypothalamic synapsins interact with mouse PR-A and PR-B in a ligand-dependent manner. Confirmation by Western blot of MS findings that synapsin-Ia and synapsin-Ib (***A***) and synapsin-IIa and synapsin-IIb (***B***) associate with PR-A and PR-B in the presence, of the PR agonist R5020. Input (0.25% of total) from hypothalamic extracts (lane 1).](enu0051724130001){#F1}

RPPA {#s4B}
----

To further explore the interactions of proteins from mouse hypothalamus with PR, we used RPPA, which provides a targeted approach and allows identification of phospho-proteins as markers of protein activity. RPPA analysis identified multiple proteins that interacted with mouse PR in a ligand-dependent and isoform-specific manner ([Tables 3](#T3){ref-type="table"} and [3-1](#T3){ref-type="table"}). In support of the present MS results, many of the identified proteins that associated with liganded PR were transcriptional regulators ([Table 3](#T3){ref-type="table"}). Additional proteins identified by RPPA that were not detected by MS have known roles in signal transduction or metabolism; a subset were phosphorylated forms of signaling proteins, including src kinase ([Table 3](#T3){ref-type="table"}).

###### 

Mouse PR-A and PR-B interact with hypothalamic proteins, identified by RPPA, in a ligand-dependent manner, with a ratio of R5020/no ligand ≥2 and *p* \< 0.05.

  ------------------------------------------------------- ---------------- ------------ ------------------------ ------------------------
  **Transcription**                                       UniProt symbol   UniProt ID   PR-A (R5020/no ligand)   PR-B (R5020/no ligand)
  Steroid-receptor coactivator-1                          NCOA1            P70365       \+                       \+
  Steroid receptor coactivator-2                          NCOA2            Q61026       \+                       \+
  Thyroid hormone receptor-associated protein complex     MED12            A2AGH6       \+                       
  c-Fos^p^                                                FOS              P01101       \+                       
  c-Jun^p^                                                JUN              P05627       \+                       
  Kruppel-like factor 4                                   KLF4             Q60793       \+                       
  Autophagy-related protein 3                             ATG3             Q9CPX6       \+                       
  Autophagy related protein 12                            ATG12            Q9CQY1       \+                       
  BCL2 antagonist/killer 1                                BAK              O08734       \+                       \+
  Forkhead box O1 (metabolism)                            FOXO1            Q9R1E0       \+                       \+
  **Signal transduction**                                                                                        
  Src kinase^p^                                           SRC              P05480       \+                       
  Signal transducer and activator of transcription 2^p^   STAT2            Q9WVL2       \+                       
  Epidermal growth factor receptor                        EGFR             Q01279       \+                       
  p70S6 kinase^p^                                         KS6B             Q8BSK8       \+                       
  Integrin-α5                                             ITA5             P11688       \+                       
  Cyclin C                                                CCNC             Q62447       \+                       
  ------------------------------------------------------- ---------------- ------------ ------------------------ ------------------------

^p^Proteins identified with phospho-specific antibodies. [Table 3-1](#tab3-1){ref-type="supplementary-material"} shows proteins identified by RPPA that associate with PR in the absence of ligand.

Two nuclear receptor coactivators, SRC-1 and SRC-2, known to be involved in PR expression and function in brain ([@B75]; [@B73]; [@B126]; [@B1]), were also detected by RPPA to interact with PR-A and PR-B in the presence of R5020 compared with no ligand. Ligand-dependent interactions with SRC-1 and SRC-2 were further confirmed by Western blot analysis ([Fig. 2](#F2){ref-type="fig"}). Two-way ANOVA on SRC-1 relative intensity showed an effect of ligand (*F* = 14.56, *p* = 10.0 × 10^--4^) such that SRC-1 interacted with PR-A and PR-B in the presence of R5020 compared with no ligand. Similarly, SRC-2 associated with both PR isoforms when bound to R5020 (*F* = 21.65, *p* = 3.0 × 10^--5^) compared with no ligand. There were differences between receptor subtypes on interaction with either SRC-1 or SRC-2 ([Fig. 2](#F2){ref-type="fig"}). Interestingly, the majority of proteins that function as transcriptional regulators, as identified by RPPA, interacted with PR-A only ([Table 3](#T3){ref-type="table"}). Furthermore, proteins involved in signal transduction identified by RPPA interacted with PR-A, but not PR-B, in the presence of agonist ([Table 3](#T3){ref-type="table"}). A transcription factor with a role in energy metabolism, FoxO1, was also identified to interact with both PR-A and PR-B. This interaction of FoxO1 with PR was further validated by Western blot ([Fig. 3](#F3){ref-type="fig"}). Confirmation of c-Fos, c-Jun, and MED12, identified by RPPA, by Western blot was not possible because the signal intensities of these proteins by Western were not strong enough to be analyzed, most likely because of the decreased sensitivity of Western blot compared with RPPA. Two other proteins identified by MS to interact with liganded PR, MAP kinase 1 and 14-3-3 protein ζ/δ, were not found to associate with PR in a ligand-dependent manner by RPPA, likely because of differences in sensitivities for specific proteins between the two techniques.

![SRC-1 and SRC-2 from hypothalamus interact with PR in a ligand-dependent manner. Western blot results show that SRC-1 (***A***) and SRC-2 (***B***) from mouse hypothalamus associate with PR-A and PR-B in the presence of the agonist R5020, but not in the absence of ligand. \**p* \< 0.05 indicates difference between the presence and absence of the ligand.](enu0051724130002){#F2}

![Hypothalamic FoxO1 interacts with mouse PR-A and PR-B when bound to the agonist, R5020. Confirmation of RPPA findings by Western blot that FoxO1 from mouse hypothalamus associates with PR-A and PR-B in the presence, but not the absence, of the PR agonist R5020. Inputs (1% of total) of FoxO1 from hypothalamic extracts (lane 1).](enu0051724130003){#F3}

Similar to the MS results above, additional proteins that selectively associated with unliganded PR compared with their liganded counterparts were identified by RPPA ([Table 3-1](#tab3-1){ref-type="supplementary-material"}).
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Proteins that interact with mouse PR-A, mouse PR-B, or both isoforms in the absence of a ligand, as identified by RPPA, with a ratio of no ligand/R5020 ≥3 and *p*\<0.05. ^p^Proteins identified with phospho-specific antibodies. Download Table 3-1, DOC file.

Ingenuity pathway analysis of PR interactome {#s4C}
--------------------------------------------

Network pathways of proteins that associate with PR, as identified by MS and RPPA, were created using Ingenuity Pathway Analysis, a program that generates protein networks using known protein interactions ([Fig. 4](#F4){ref-type="fig"}). The highest scoring network pathway depicted shows proteins known to associate with PR (e.g., NCOA1 and NCOA2) and novel interactions of proteins from brain (e.g., synapsins and tubulin complexes) with PR identified in the present study ([Fig. 4](#F4){ref-type="fig"}).

![Network generated by Ingenuity Pathway Analysis (IPA) showing proteins from hypothalamus that associate with liganded PR-A and PR-B. Shaded proteins were identified to associate with both PR-A and PR-B (blue), PR-A only (green), or PR-B only (orange) in the present study. Unshaded proteins (white) were added to the network based on curated relationships in the IPA database. BAK1, BCL2 antagonist/killer 1; DSP, desmoplakin; JUP, junction plakoglobin; Hbbb1, hemoglobin subunit β-1; HNRNPDL, heterogeneous nuclear ribonucleoprotein D-like; NCOA1/SRC-1, steroid receptor coactivator-1; NCOA2/SRC-2, steroid receptor coactivator-2; PGR, progesterone receptor; SNCA, α-synuclein; SYN, synapsin; TUB, tubulin; YWHAZ, 14-3-3 protein ζ/δ.](enu0051724130004){#F4}

The use of the two proteomics approaches, MS and RPPA, enabled a more comprehensive identification of novel and known proteins that interacted with PR-A and PR-B in a ligand-dependent manner. Although MS analysis of PR-protein pull-down assays is an unbiased approach, it is less sensitive than RPPA for detection of lower-abundance proteins such as SRC-1 and SRC-2. RPPA, on the other hand, is an antibody-based targeted proteomic approach and is limited to the target antigens for which antibodies are available. For example, our RPPA platform does not have validated antibodies to synaptic proteins, the largest functional groups identified by MS. Therefore, MS and RPPA served as complementary approaches for identification of PR-interacting proteins.

Effects of progesterone and estradiol on synapsin-I-- and PSD95-containing synapses {#s4D}
-----------------------------------------------------------------------------------

To understand whether P4 could alter synapsin-I levels, primary rat cortical neurons with a mature morphology (DIV 23--25) were treated with 1 n[m]{.smallcaps} P4, 1 n[m]{.smallcaps} E2, or 1 n[m]{.smallcaps} P4 and E2 for 24 h. Subsequently, cells were fixed and immunostained for synapsin-I, postsynaptic density protein 95 (PSD95), and MAP2 (marker of neuronal morphology). Quantitative analysis of immunofluorescence revealed that after exposure to P4, there was an increase in the linear density of synapsin-I puncta ([Fig. 5*A*, *B*](#F5){ref-type="fig"}). E2, on the other hand, did not alter synapsin-I linear density from control (vehicle) levels; the combined treatment of P4 and E2 also had no effect on synapsin-I levels (synapsin-I puncta linear density per 10 µm: control, 13.0 ± 0.71; P4, 16.6 ± 0.53; E2, 14.2 ± 0.49; P4 + E2, 11.6 ± 0.58; [Fig. 5*A*, *B*](#F5){ref-type="fig"}). When we examined levels of the postsynaptic protein PSD95, no change in linear density was observed in cells treated with P4. However, an increase in the PSD95 linear density was observed in cells treated with E2 or P4 plus E2 (PSD95 puncta linear density per 10 µm: control, 10.7 ± 0.85; P4, 13.1 ± 0.69; E2, 16.6 ± 0.68; P4 + E2, 16.4 ± 0.74; [Fig. 5*A*, *C*](#F5){ref-type="fig"}). We next sought to determine whether the changes in synaptic protein linear density induced by P4, E2, or P4 plus E2 treatments reflected an overall change in synapse number; synapses were defined as synapsin-I puncta overlapping with PSD95. In line with the observed increases in synapsin-I and PSD95 linear density in P4- and E2-treated cells, respectively, an increase in synapse number was also observed, whereas the combined treatment of P4 and E2 did not alter synapse number from control levels (synaptic puncta linear density per 10 µm: control, 9.9 ± 0.80; P4, 14.3 ± 0.49; E2, 14.2 ± 0.51; P4 + E2, 12.15 ± 0.59; [Fig. 5*A*, *D*](#F5){ref-type="fig"}).

![Progesterone (P4) and estradiol (E2) alter synapse number and synaptic protein expression. ***A***, Representative confocal images of primary rat cortical neurons treated with 1 n[m]{.smallcaps} P4, 1 n[m]{.smallcaps} E2, or both for 24 h. Images are for synapsin-I (green) and PSD95 (red) along MAP2-positive dendrites (blue). Open arrowheads indicate colocalized synapsin-I and PSD95 puncta and thus, synapses. ***B***, Quantitative analysis of synapsin-I linear density; treatment with P4 increased synapsin-I density compared with control (vehicle) condition. ***C***, PSD95 linear density was increased over control levels after treatment with E2 alone or combined P4 and E2 treatment. ***D***, Measurement of synaptic puncta, defined as synapsin-I puncta positive for PSD95, was increased after treatment with either P4 or E2. \*\**p* \< 0.01; \*\*\**p* \< 0.001; scale bar = 5 µm.](enu0051724130005){#F5}

Discussion {#s5}
==========

Using the proteomics-based approaches of MS and RPPA, we have identified proteins from female mouse hypothalamus that form complexes with PR-A, PR-B, or both in a ligand-dependent manner. Of the proteins that associated with agonist-bound PR, synaptic modulators made up the largest group, providing evidence for novel roles of PR in synaptic plasticity. Furthermore, in primary cortical neuronal cultures, we provide evidence that progesterone increases synapses containing synapsin-I protein, which selectively associated with ligand-bound PR. The other major protein groups from hypothalamus that interacted with the PR isoforms are kinases and signaling proteins, transcriptional and translational regulators, and proteins linked to energy metabolism.

PR and synaptic modulation {#s5A}
--------------------------

Progestins modulate dendritic spine density and synapse numbers in the female rat hippocampus, ventromedial hypothalamus (VMH), and prefrontal cortex, and in cultured rat cortical neurons ([@B122]; [@B70]; [@B19]; [@B39]; [@B22]; [@B94]). Most prior studies have examined the combined effects of E2 and P4 on dendritic spines, revealing that E2 increases, whereas E2 plus P4 decreases, dendritic spines in the hippocampus ([@B70]; [@B78]), prefrontal cortex ([@B22]), and hypothalamus ([@B39]). Previously, it has been shown that P4 treatment for 2 wks increases dendritic spine density in cortical pyramidal neurons of ovariectomized rats ([@B19]). The present findings extended those of [@B19] to reveal that treatment with P4 for 24 h increases synapses in cortical neurons, as indicated by immunohistochemical localization of synapsin-I and PSD95 in the newly formed synapses. In further support of progestin-dependent synapse modulation, estradiol-induced PR have been detected in neuronal processes in the hypothalamus ([@B10]) and dendritic spines and axon terminals in the hippocampus ([@B120]; [@B72]) of female rodents.

The present findings, that synaptic proteins from mouse brain interact with PR, provide insight into novel mechanisms for progestin effects on synaptic functions. As identified by MS and Western blot, synapsin-I and synapsin-II interacted with both PR isoforms in a ligand-dependent manner. In addition, P4 increased synaptic density in rat primary cortical neurons, indicated by an increase in synapsin-I--positive puncta, suggesting that synapsin-I function in P4-mediated synapse addition is conserved among species. The present findings confirm the synaptogenic role of progestins and suggest a function for synapsin-I in progestin-mediated synapse formation. Synapsins may influence cortical synapses through direct association with PR or, alternatively, may function with PR indirectly or through PR-independent pathways.

Synapsins, including synapsin-I and synapsin-II, are presynaptic phosphoproteins that are integral in axon formation, synaptic maturation, transmission, and remodeling in excitatory synapses ([@B21]; [@B32]; [@B13]; [@B17]). Synapsins contain binding sites for MAPK/Erk and src kinase ([@B51]; [@B33]), kinases identified in the present study to interact with ligand-bound PR. Taken together, these findings suggest that PR increase synapses through regulating expression, transport, or phosphorylation of synapsins. Given the rapid effects of estrogens on synapses via kinases and synaptic proteins ([@B107]; [@B101]), it will be important to explore the function of kinases identified here on progestin-mediated synapse formation.

Multiple synaptic proteins interacted with PR in an isoform-specific manner. For example, synaptogyrin-III, which is upregulated in the hypothalamus by estradiol ([@B67]), interacted only with PR-A, suggesting a role for this protein in hormone-dependent synaptic changes. Synapsin-III, which is expressed in cell bodies of neuronal progenitors and has been implicated in neurogenesis ([@B52]), interacted only with PR-B, indicating a role for PR-B in neurogenesis ([@B5]; [@B4]). Interestingly, tubulins, which are components of microtubules that provide structural framework for synaptic junctions, postsynaptic densities, and synaptic vesicles ([@B54]; [@B128]), formed complexes with PR in an isoform-specific and ligand-dependent manner, another novel finding of the current study. Tubulinβ-2A and tubulinβ-4B, which are upregulated by estradiol in female hippocampus, were associated with liganded PR in the present study ([@B83]; [@B97]). Taken together, these findings suggest an important role for tubulins in progestin-mediated synaptic plasticity in the brain.

PR and signal transduction {#s5B}
--------------------------

PR, acting through kinase activation, exert rapid effects in the brain ([@B69]; [@B112]; [@B94]). In further support of rapid effects of PR in the brain, we found that MAPK1 associated with liganded PR-B, but not PR-A. Consistent with these findings, MAPK1 associates with and phosphorylates PR-B, but not PR-A, in P4-treated breast cancer cells ([@B24]; [@B14]). In addition, we detected hormone-dependent interactions between src kinase and EGFR with PR-A, but not PR-B. These differential interactions of signaling molecules with PR may be important for isoform-specific rapid effects of PR in brain.

PR and energy metabolism {#s5C}
------------------------

Although the profound effects of estradiol on decreasing feeding and weight gain and increasing activity in women and female rodents is well known ([@B8]; [@B23]; [@B11]), the effects of progesterone on metabolism are less studied. However, progesterone attenuates the effects of estrogens on food intake and carbohydrate metabolism in female primates and women, respectively ([@B55]; [@B27]; [@B71]). The present findings reveal that creatine kinase B and phytanoyl COA-hydroxylase interacting protein-like, both involved in energy metabolism ([@B48]; [@B99]), associated with PR-A, but not PR-B, implicating a function for hypothalamic PR-A in energy homeostasis.

In further support of PR function in energy homeostasis, the transcriptional regulator FoxO1 interacted with both PR isoforms. FoxO1 is expressed in energy regulation centers, including the VMH and arcuate nucleus ([@B57]; [@B34]), and enhances food intake by increasing neuropeptide Y and agouti-related protein mRNA expression ([@B59]; [@B45]). In addition, FoxO1 attenuates leptin signaling and is regulated by leptin ([@B124]; [@B89]). Taken together with the studies above, the present findings suggest that hypothalamic PR function in energy homeostasis and indicate the need for further study of progestins in food intake and energy metabolism.

PR and transcriptional regulation {#s5D}
---------------------------------

PR-A and PR-B act as transcription factors in concert with other transcriptional regulators, including nuclear receptor coactivators and RNA polymerases ([@B79]; [@B113]; [@B28]). The present findings reveal that SRC-1 and SRC-2 from hypothalamus interact with agonist-bound PR-A and PR-B, consistent with our earlier work that these coactivators are coexpressed with the PR isoforms in the female mouse hypothalamus ([@B1]) and function in the brain to modulate PR-dependent behaviors ([@B73]).

Although the role of the transcription factor FoxO1 in energy metabolism is discussed above, it has also been linked to stress and depression. FoxO1 expression is upregulated by glucocorticoids ([@B87]) and is downregulated by antidepressants ([@B86]). Thus, exploring a potential role of FoxO1 and PR interaction may provide more insight into the role of progesterone in stress disorders.

PR-A, but not PR-B, interacted with MED12, which bridges transcription factors with RNA polymerases and is integral for vertebrate neuronal development ([@B119]; [@B92]; [@B58]). In humans, MED12 mutations lead to X-linked mental retardation ([@B84]; [@B91]; [@B100]). Taken together, the present findings provide a mechanism by which progestins mediate brain development ([@B88]; [@B64]) through PRA-MED12 interactions. In future studies, it will be important to explore whether mutations in MED12 disrupt interactions with PR and alter brain development.

Based on previous studies and the current findings, a majority of tubulins and synaptic proteins, including synapsin isoforms and α-synuclein, likely associate with PR through a 26S proteasome complex as shown by Ingenuity Pathway Analysis ([Fig. 4](#F4){ref-type="fig"}). Interestingly, 26S protease subunit associated with PR-B, but not PR-A, in the current study, suggesting differential downregulation of the PR isoforms after P4 treatment ([@B60]). Ingenuity Pathway Analysis incorporates previously identified proteins that are known to associate with PR, in either the liganded or unliganded state, with the present findings. For example, proteins known from previous studies to interact with PR, including a molecular chaperone hsp90 ([@B29]; [@B50]; [@B115]), actin (known for its role in PR- mediated growth cone formation and modulation of dendritic spines; [@B94]; [@B121]), and nuclear factor-κB (a stress-response regulator; [@B26]), were added to the network ([Fig. 5](#F5){ref-type="fig"}) by Ingenuity Pathway Analysis. However, given that the present study focused on hypothalamic proteins that interact with PR in a ligand-dependent manner, only these proteins from the current findings were added to the network (shaded proteins in [Fig. 5](#F5){ref-type="fig"}). In summary, this network confirms previously known interactions of PR with nuclear receptor coactivators (e.g., SRC-1/NCOA1 and SRC-2/NCOA2) and provides evidence for novel mechanisms by which progestins modulate synapses, revealing multiple regulatory levels of PR action in the brain.

Although genome-wide analysis of PR binding sites in mouse uterus ([@B93]) and computational models have been used to predict the human PR interactome ([@B63]), to the best of our knowledge, the PR interactome has not been previously analyzed. Despite different approaches used in the previous studies ([@B93]; [@B63]), the present findings of association of PR with transcriptional regulators, multiple tubulin isoforms, Src kinase, and EGFR were consistent with these published reports. Other studies have focused on receptor-dependent transcriptome or proteome of steroid receptors, including PR and estrogen receptors ([@B111]; [@B125]). Finally, proximity mapping has been used in cultured cells to identify proteins showing ligand-dependent interactions with receptors for glucocorticoids and androgens ([@B61]). Although these studies have found some interacting partners similar to those of the present study, including SRC-1, SRC-2, and MED12, none of these experiments investigated interacting proteins from the brain, and more specifically the hypothalamus. Therefore, the current study has identified a number of novel proteins interacting with PR, including synaptic proteins and regulators of metabolism.

A comprehensive and novel approach of combining MS and RPPA enabled us to identify a diverse and new group of protein complexes in the brain that interact with PR in a ligand- and isoform-specific manner. Although MS is an unbiased approach for identification of novel proteins, it requires large amounts of protein input, which could result in difficulty identifying low-abundance proteins. RPPA complemented the MS and expanded the coverage for low-abundance proteins. Both approaches identified many proteins in three major groups, including those with roles in transcription, metabolism, and signal transduction. In future studies, it will be important to investigate interactions between endogenous hypothalamic PR with proteins using different approaches (e.g., coimmunoprecipitation assays) to confirm and extend the current findings.

Through the identification of multiple components of PR complexes in the brain, the current study provides insights into various mechanisms of PR in physiology and disease. In addition, identification of protein complexes from female mouse hypothalamus that interact differentially with PR-A and PR-B sheds light on mechanisms that may contribute to PR isoform--specific functions. This study provides a novel role for synapsin-I in progestin-induced increase in synapses. These findings offer further evidence for overlapping pathways in genomic and nongenomic regulation in synaptic physiology and energy metabolism. In future studies, it will be important to apply the present strategies to identify factors involved in ligand-independent activation of PR ([@B30]; [@B68]; [@B116]) that will provide important insights into PR action in physiology, behavior, and disease.
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Synthesis {#s6}
=========

Reviewing Editor: Jeffrey Blaustein, University of Massachusetts

Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: Robert Handa

There is great interest in your manuscript, in particular identifying the protein partners of PR in the hypothalamus, and everybody is in agreement that the work should be published. However, there are some issues that will need to be dealt with:

1\. Please remove reference to your study being "the first study to provide a progestin-dependent proteomic \..." Besides the fact that one can never know that they are first to do something, one reviewer points out that, while no one else may have approached this question in precisely the same way previously, the claim is perhaps stronger than is warranted, based on the literature and the data presented.

2\. Questions were raised in the first review of this MS regarding the novelty of the findings, given that previous studies in both neural and non-neural tissues have demonstrated some of the protein interactions shown here (Reviewer 1 "the fact that in mouse there are now similar findings is not all that groundbreaking"). While not as complete as the present study, previous work (by Edwards for example) in non-neural tissues demonstrated some of the kinase interactions reported here, while papers cited in the reference list demonstrated receptor subtype specific interactions with steroid receptor coactivator-1 and -2 (Molenda-Figueira et al Endocrinology 2008; Yore et al Neuroscience 2010) consistent with the observations reported here. That progesterone may promote synapse formation in the cortex was suggested eight years ago by the work of Chen at al (Cereb Cortex. 2009; a paper that is not in the reference list) who reported that progesterone alone was as effective as estradiol in restoring the dendritic spine densities of primary sensorimotor cortical pyramidal neurons, in ovariectomized rats.

3\. It was suggested that the cortical culture addition actually detracts from the paper, and that, the paper of Chen et al., could simply be referred to. That is your decision, but it is most important to focus on the protein interaction data in the hypothalamus, which are definitely worthy of publication. Either way, it is essential to tone down the discussion of cortical spines, and address directly in the discussion that this was done in cortex, not hypothalamus.
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